Deborah S. Snyder, DVM
Affiliations: | Psychiatry | University of Colorado, Boulder, Boulder, CO, United States |
Area:
PrimatologyWebsite:
http://rrahvets.comGoogle:
"Deborah Snyder"Mean distance: 106866 (cluster 7) | S | N | B | C | P |
Parents
Sign in to add mentor| Melinda A. Novak | research assistant | 1978-1979 | U Mass Amherst |
| Martin Reite | research assistant | 1979-1983 | University of Colorado, Denver |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mei M, Tsai NC, Mokhtari S, et al. (2020) Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
| Salhotra A, Yang D, Mokhtari S, et al. (2020) Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage-Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
| Al Malki MM, Tsai N, Palmer J, et al. (2020) Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial Blood. 136: 49-50 |
| Ngo D, Mac S, Yang D, et al. (2020) Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis Blood. 136: 21-22 |
| DeFilipp Z, Ancheta R, Liu Y, et al. (2019) Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
| Salhotra A, Hui S, Yang D, et al. (2019) Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
| Mei M, Gupta R, O'Donnell M, et al. (2019) Post-allogeneic eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with PNH clones. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
| Yao JM, Yang D, Mokhtari S, et al. (2019) Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis Blood. 134: 4518-4518 |
| Ali H, Snyder D, Stiller T, et al. (2019) Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning Blood. 134: 669-669 |
| Sandhu KS, Aldoss I, Yang D, et al. (2019) A Retrospective Study of Venetoclax-Based Salvage Regimen As a Bridge to Allogeneic Hematopoietic Cell Transplantation (HCT) in High-Risk Acute Myeloid Leukemia (AML) Patients Biology of Blood and Marrow Transplantation. 25: S102-S103 |